Husk på, at en investeret opsparing kan gå både op og ned i værdi. Selvom opsparing i aktier historisk set har givet gode langsigtede afkast, er det ingen garanti for fremtidige afkast. Der er en risiko for, at du ikke får de investerede penge tilbage.
Mæglerstatistik
Ingen data fundet
Corporate Actions
Se alle
Næste begivenhed
2025 Q4-regnskab
26. mar. 2026
Tidligere begivenheder
2025 Q3-regnskab
5. nov.
2025 Q2-regnskab
12. aug.
2025 Q1-regnskab
14. maj
2024 Q4-regnskab
24. mar.
2024 Q3-regnskab
12. nov. 2024
Data hentes fra Quartr, FactSet
Andre har kigget på
Vis mere information
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Nyheder og Analyser
Nyheder & Pressemeddelelse
Analyser
12 nov. 01:40
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11 nov. 21:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
7 nov. 13:00
∙
Pressemeddelelse
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
5 nov. 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
12 aug. 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
16 jun. 13:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
14 maj 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
24 mar. 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
12. november 2024 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
13. september 2024 02:34
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
11. september 2024 20:04
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
10. september 2024 11:00
∙
Pressemeddelelse
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
27. august 2024 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
13. august 2024 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
13. maj 2024 20:10
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
24. april 2024 01:36
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
23. april 2024 20:17
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
22. april 2024 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
28. marts 2024 20:28
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
13. november 2023 21:05
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Relaterede Produkter
Bull & Bear
2025 Q3-regnskab
Kun PDF-version
31 dage siden
Nyheder og Analyser
Nyheder & Pressemeddelelse
Analyser
12 nov. 01:40
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11 nov. 21:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
7 nov. 13:00
∙
Pressemeddelelse
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
5 nov. 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
12 aug. 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
16 jun. 13:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
14 maj 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
24 mar. 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
12. november 2024 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
13. september 2024 02:34
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
11. september 2024 20:04
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
10. september 2024 11:00
∙
Pressemeddelelse
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
27. august 2024 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
13. august 2024 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
13. maj 2024 20:10
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
24. april 2024 01:36
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
23. april 2024 20:17
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
22. april 2024 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
28. marts 2024 20:28
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
13. november 2023 21:05
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Nasdaq
Antal
Køb
0
29,83
Sælg
Antal
29,91
0
Seneste handel
Tid
Pris
Antal
Købere
Sælgere
-
-
-
-
-
Højest
30
VWAP
29,78
Lavest
28,95
OmsætningAntal
26,4 887.812
VWAP
29,78
Højest
30
Lavest
28,95
OmsætningAntal
26,4 887.812
Risikoinformation vedrørende aktiehandel
Husk på, at en investeret opsparing kan gå både op og ned i værdi. Selvom opsparing i aktier historisk set har givet gode langsigtede afkast, er det ingen garanti for fremtidige afkast. Der er en risiko for, at du ikke får de investerede penge tilbage.
Mæglerstatistik
Ingen data fundet
Andre har kigget på
Vis mere information
Corporate Actions
Se alle
Næste begivenhed
2025 Q4-regnskab
26. mar. 2026
Tidligere begivenheder
2025 Q3-regnskab
5. nov.
2025 Q2-regnskab
12. aug.
2025 Q1-regnskab
14. maj
2024 Q4-regnskab
24. mar.
2024 Q3-regnskab
12. nov. 2024
Data hentes fra Quartr, FactSet
Relaterede Produkter
Bull & Bear
2025 Q3-regnskab
Kun PDF-version
31 dage siden
Nyheder og Analyser
Nyheder & Pressemeddelelse
Analyser
12 nov. 01:40
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11 nov. 21:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
7 nov. 13:00
∙
Pressemeddelelse
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
5 nov. 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
12 aug. 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
16 jun. 13:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
14 maj 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
24 mar. 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
12. november 2024 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
13. september 2024 02:34
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
11. september 2024 20:04
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
10. september 2024 11:00
∙
Pressemeddelelse
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
27. august 2024 12:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
13. august 2024 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
13. maj 2024 20:10
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
24. april 2024 01:36
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
23. april 2024 20:17
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
22. april 2024 11:00
∙
Pressemeddelelse
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
28. marts 2024 20:28
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
13. november 2023 21:05
∙
Pressemeddelelse
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
Se alle
Næste begivenhed
2025 Q4-regnskab
26. mar. 2026
Tidligere begivenheder
2025 Q3-regnskab
5. nov.
2025 Q2-regnskab
12. aug.
2025 Q1-regnskab
14. maj
2024 Q4-regnskab
24. mar.
2024 Q3-regnskab
12. nov. 2024
Data hentes fra Quartr, FactSet
Relaterede Produkter
Bull & Bear
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Nasdaq
Antal
Køb
0
29,83
Sælg
Antal
29,91
0
Seneste handel
Tid
Pris
Antal
Købere
Sælgere
-
-
-
-
-
Højest
30
VWAP
29,78
Lavest
28,95
OmsætningAntal
26,4 887.812
VWAP
29,78
Højest
30
Lavest
28,95
OmsætningAntal
26,4 887.812
Risikoinformation vedrørende aktiehandel
Husk på, at en investeret opsparing kan gå både op og ned i værdi. Selvom opsparing i aktier historisk set har givet gode langsigtede afkast, er det ingen garanti for fremtidige afkast. Der er en risiko for, at du ikke får de investerede penge tilbage.